ReviewCurrent pharmaceutical biotechnology2011
Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
Review in Current pharmaceutical biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Changes in protein structure monitored by use of gas-phase hydrogen/deuterium exchange.Proteomics · 2015Article
- Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.Molecular pharmaceutics · 2013Article
- Mass spectrometry-based methods to study protein architecture and dynamics.Protein science : a publication of the Protein Society · 2013Review
- Platform dependencies in bottom-up hydrogen/deuterium exchange mass spectrometry.Molecular & cellular proteomics : MCP · 2013Article
- Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Nature reviews. Drug discovery · 2012Review
- Transferrin as a model system for method development to study structure, dynamics and interactions of metalloproteins using mass spectrometry.Biochimica et biophysica acta · 2012Review
- Post-production protein stability: trouble beyond the cell factory.Microbial cell factories · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mass spectrometry has already become an indispensable tool in the analytical armamentarium of the biopharmaceutical industry, although its current uses are limited to characterization of covalent structure of recombinant protein drugs. However, the scope of applications of mass spectrometry-based methods is beginning to expand to include characterization of the higher order structure and dynamics of biopharmaceutical products, a development which is catalyzed by the recent progress in mass spectrometry-based methods to study higher order protein structure. The two particularly promising methods that are likely to have the most significant and lasting impact in many areas of biopharmaceutical analysis, direct ESI MS and hydrogen/deuterium exchange, are focus of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.